Adjuvant treatment of severe varicella pneumonia with intravenous varicella zoster virus-specific immunoglobulins.

Abstract

Varicella zoster virus (VZV) pneumonia is associated with significant mortality, especially in the immunocompromised host. VZV-specific immunoglobulins (VZIG) are currently used as post-exposure prophylaxis for at-risk patients, but not as adjunctive therapy. A novel case of VZV pneumonia in an immunocompromised patient, treated successfully with intravenous VZIG in combination with acyclovir, is reported here.

• Authors: Davide Mangioni, Giacomo Grasselli, Chiara Abbruzzese, Antonio Muscatello, Andrea Gori, Alessandra Bandera
• Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (Int J Infect Dis) Vol. 85 Pg. 70-73 (Aug 2019) ISSN: 1878-3511 [Electronic] Canada
• PMID: 31132473 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Adjuvants, Immunologic
• Antibodies, Viral
• Antiviral Agents
• Acyclovir

Topics

• Acyclovir (therapeutic use)
• Adjuvants, Immunologic (administration & dosage, therapeutic use)
• Administration, Intravenous
• Adult
• Antibodies, Viral (administration & dosage, therapeutic use)
• Antiviral Agents (therapeutic use)
• Herpesvirus 3, Human (immunology)
• Humans
• Immunocompromised Host
• Male
• Pneumonia, Viral (drug therapy)
• Varicella Zoster Virus Infection (drug therapy)